189 related articles for article (PubMed ID: 37184108)
21. SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant.
Cheung AH; Wong KY; Chau SL; Xie F; Mui Z; Li GY; Li MSC; Tong J; Ng CS; Mok TS; Kang W; To KF
Pathology; 2024 Jun; 56(4):504-515. PubMed ID: 38413251
[TBL] [Abstract][Full Text] [Related]
22. Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report.
Kito Y; Kawashima K; Saigo C; Hasegawa M; Nomura S; Mikamo T; Hanamatsu Y; Matsuo Y; Takeuchi T
Diagn Pathol; 2022 Feb; 17(1):29. PubMed ID: 35151345
[TBL] [Abstract][Full Text] [Related]
23. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
[TBL] [Abstract][Full Text] [Related]
24. SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.
Velut Y; Decroix E; Blons H; Alifano M; Leroy K; Petitprez F; Boni A; Garinet S; Biton J; Cremer I; Wislez M; Boudou-Rouquette P; Arrondeau J; Goldwasser F; Fournel L; Damotte D; Mansuet-Lupo A
Lung Cancer; 2022 Jul; 169():13-21. PubMed ID: 35597058
[TBL] [Abstract][Full Text] [Related]
25. SMARCA4-Deficient Undifferentiated Tumor of Lung Mass-A Rare Tumor With the Rarer Occurrence of Brain Metastasis: A Case Report and Review of the Literature.
Yadav R; Sun L; Salyana M; Eric M; Gotlieb V; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096221074864. PubMed ID: 35356840
[TBL] [Abstract][Full Text] [Related]
26. The clinicopathological features of BRG1-deficient non-small cell lung cancer and its response to immunotherapy: A single-center retrospective study.
Zhang J; Zhao R; Xu H; Dong L; Chen X
Ann Diagn Pathol; 2023 Dec; 67():152192. PubMed ID: 37639838
[TBL] [Abstract][Full Text] [Related]
27. SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature.
Nambirajan A; Singh V; Bhardwaj N; Mittal S; Kumar S; Jain D
Arch Pathol Lab Med; 2021 Jan; 145(1):90-98. PubMed ID: 33367658
[TBL] [Abstract][Full Text] [Related]
28. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.
Sauter JL; Graham RP; Larsen BT; Jenkins SM; Roden AC; Boland JM
Mod Pathol; 2017 Oct; 30(10):1422-1432. PubMed ID: 28643792
[TBL] [Abstract][Full Text] [Related]
29. [Clinical characteristics and prognosis analysis of 17 cases of SMARCA4-deficient chest tumors].
Cao XN; Li Z; Wang QY
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):325-331. PubMed ID: 38599807
[No Abstract] [Full Text] [Related]
30. SMARCA4 as a support for the differential diagnosis of poorly differentiated lung carcinomas.
Panozzi M; Alì G; Proietti A; Melfi F; Zirafa CC; Lucchi M; Fontanini G
Pathologica; 2023 Jun; 115(3):164-171. PubMed ID: 37387441
[TBL] [Abstract][Full Text] [Related]
31. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Cortellini A; Ricciuti B; Borghaei H; Naqash AR; D'Alessio A; Fulgenzi CAM; Addeo A; Banna GL; Pinato DJ
Cancer; 2022 Aug; 128(16):3067-3079. PubMed ID: 35727053
[TBL] [Abstract][Full Text] [Related]
32. Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.
Shi M; Pang L; Zhou H; Mo S; Sheng J; Zhang Y; Liu J; Sun D; Gong L; Wang J; Zhuang W; Huang Y; Chen Z; Zhao Y; Li J; Huang Y; Yang Y; Fang W; Zhang L
Lung Cancer; 2024 May; 192():107818. PubMed ID: 38763102
[TBL] [Abstract][Full Text] [Related]
33. The Genomic Landscape of
Schoenfeld AJ; Bandlamudi C; Lavery JA; Montecalvo J; Namakydoust A; Rizvi H; Egger J; Concepcion CP; Paul S; Arcila ME; Daneshbod Y; Chang J; Sauter JL; Beras A; Ladanyi M; Jacks T; Rudin CM; Taylor BS; Donoghue MTA; Heller G; Hellmann MD; Rekhtman N; Riely GJ
Clin Cancer Res; 2020 Nov; 26(21):5701-5708. PubMed ID: 32709715
[TBL] [Abstract][Full Text] [Related]
34. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
Nambirajan A; Jain D
Semin Diagn Pathol; 2021 Sep; 38(5):83-89. PubMed ID: 34147303
[TBL] [Abstract][Full Text] [Related]
35. [Thoracic
Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149
[TBL] [Abstract][Full Text] [Related]
36. SMARCA4 (BRG1) and SMARCB1 (INI1) expression in TTF-1 negative neuroendocrine carcinomas including merkel cell carcinoma.
Gandhi JS; Alnoor F; Sadiq Q; Solares J; Gradowski JF
Pathol Res Pract; 2021 Mar; 219():153341. PubMed ID: 33581550
[TBL] [Abstract][Full Text] [Related]
37. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.
Tagal V; Wei S; Zhang W; Brekken RA; Posner BA; Peyton M; Girard L; Hwang T; Wheeler DA; Minna JD; White MA; Gazdar AF; Roth MG
Nat Commun; 2017 Jan; 8():14098. PubMed ID: 28102363
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis.
Talvitie EM; Liljeroos L; Vilhonen H; Orte K; Leivo I; Kallajoki M; Taimen P
Neoplasia; 2022 Oct; 32():100832. PubMed ID: 35964518
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
[TBL] [Abstract][Full Text] [Related]
40. Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab.
Lin YT; Li CF; Wu HC; Jan YH; Kuo YH
Front Immunol; 2023; 14():1131448. PubMed ID: 37051241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
